Selecting the Right U.S. Agent for a Smooth QMSR Transition

For foreign medical device manufacturers preparing for the transition to the Quality Management System Regulation (QMSR), selecting a U.S. Agent involves more than just fulfilling a basic registration requirement. While the agent's official role is to act as a point of contact with the FDA, their support during the QMSR transition can vary significantly. How can manufacturers effectively evaluate the scope of QMSR-related services offered by a U.S. Agent to ensure a smooth transition by the compliance deadline? Beyond standard communication and registration duties, what specific services constitute comprehensive QMSR transition support? This might include conducting a gap analysis between a manufacturer's current ISO 13485:2016-certified quality system and the new requirements outlined in the QMSR, which incorporates the ISO standard by reference but retains specific elements of 21 CFR Part 820. Does the support extend to revising key documentation, such as the quality manual and standard operating procedures (SOPs), to align with the harmonized regulation? Furthermore, manufacturers should consider the agent's role in preparing the organization for FDA inspections under the new QMSR framework. What level of guidance is typically provided for adapting internal audit programs and management reviews? In assessing potential U.S. Agent partners, what criteria help distinguish between a basic registered agent and a strategic partner offering in-depth support for navigating the practical implementation of QMSR, ultimately ensuring sustained compliance in the U.S. market? --- *This Q&A was AI-assisted and reviewed for accuracy by Lo H. Khamis.*